All Research Papers Published In Cancer Cell

Research Article
5
10.1016/j.ccell.2025.04.005

Immune evolution in pre-invasive lung adenocarcinoma.

Jun 01, 2025
Cancer cell
Adithya Balasubramanian + 1 more +1

Research Article
15
10.1016/j.ccell.2025.04.013

Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis.

Jun 01, 2025
Cancer cell
Derek Dang + 44 more +44

Research Article
3
10.1016/j.ccell.2025.03.007

A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies.

Jun 01, 2025
Cancer cell
Ioanna Mosialou + 33 more +33

Research Article
1
10.1016/j.ccell.2025.04.014

Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target.

Jun 01, 2025
Cancer cell
Shiekh Tanveer Ahmad + 36 more +36

Germline loss-of-function (LOF) variants in Elongator acetyltransferase complex subunit 1 (ELP1) are the most prevalent predisposing genetic events in childhood medulloblastoma (MB), accounting for ∼30% of the Sonic hedgehog (SHH) 3 subtype. The mechanism(s) by which germline ELP1 deficiency provokes SHH-MB pathogenesis remain unknown. Genetically engineered mice mimicking heterozygous Elp1 LOF (Elp1HET) seen in affected germline carriers exhibit hallmark features of premalignancy in cerebellar granule neuron progenitors (GNPs), including increased DNA replication stress, genomic instability, accelerated cell cycle, and stalled differentiation. Orthotopic transplantation of Elp1HET GNPs harboring somatic Ptch1 inactivation yields SHH-MB-like tumors with compromised p53 signaling, providing a plausible explanation for the exclusivity of ELP1-associated MBs in the SHH-3 subtype. Preclinical treatment of ELP1-mutant patient-derived xenografts with an FDA-approved MDM2 inhibitor reactivates p53-dependent apoptosis and extends survival. Our findings functionally substantiate the role of ELP1 deficiency in SHH-MB predisposition and nominate therapeutics targeting MDM2 as a rational treatment option.

Addendum
4
10.1016/j.ccell.2025.05.009

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.

Jun 01, 2025
Cancer cell
Kevin Bi + 29 more +29

Research Article
10.1016/j.ccell.2025.04.008

Stromal barriers to the abscopal effect.

May 01, 2025
Cancer cell
Tian V Tian + 1 more +1

Research Article
3
10.1016/j.ccell.2025.03.014

The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative.

Apr 01, 2025
Cancer cell
Faiyaz Notta + 99 more +99

Research Article
47
10.1016/j.ccell.2025.03.006

Navigating Established and Emerging Biomarkers for Immune Checkpoint Inhibitor Therapy

Mar 27, 2025
Cancer cell
Stephen L Wang + 1 more +1

Research Article
10.1016/j.ccell.2025.02.021

An innovative ALA-CART platform exhibits high efficacy against cancers.

Mar 01, 2025
Cancer cell
Jiasheng Wang + 1 more +1

Research Article
31
10.1016/j.ccell.2024.11.010

Breaking the mold: Unconventional T cells in cancer therapy.

Mar 01, 2025
Cancer cell
Yan-Ruide Li + 4 more +4